Abstract: A surgical retractor device has a housing with press arms coupled thereto, each arm having rotational movement in a plane, and a gripping member pivoting at right angle with the plane, at an outer end of the arm; an attachment means at an inner end of the arm; an opening and closing mechanism with rotatable press arm attachment structures attaching the attachment means of the press arms, symmetrically positioned from a centerline of the device; rotatable handle attachment structures, and; a transfer mechanism transferring rotation from handle attachment structures to press arm attachment structures. The device also has handles for operating the opening and closing mechanism. Each handle has a handle attachment means at an inner end of the handle for attachment to the handle attachment structures; and, a handle structure. The handles have a rotational movement in the plane and are symmetrically positioned from the centerline of the device.

Abstract: A survey instrument comprising a single point and a point cloud measuring functionality, a communication interface, and a computing unit. The point cloud measuring functionality configured to emit a scanning beam along a first measuring axis and to advance the first measuring axis along a scanning pattern. The point cloud measuring functionality is configured to generate point cloud data representing a setting. The single point measuring functionality is configured to emit a measuring beam along a second measuring axis. The first measuring axis is referenced to the second measuring axis. The communication interface is configured to receive model data representing at least a part of the setting and comprising referencing data to an external coordinate system. The computing unit is configured to identify cardinal features in the point cloud data as well as in the model data.

Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having: (I) a cancer cell having one or both of (i) decreased TREX1 level and/or activity, and (ii) increased cGAS/STING signaling pathway activity, e.g., as compared to a reference level, and/or (II) an elevated level of cGAMP in a serum or tumor sample obtained from the subject, e.g., as compared to a reference level.

Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased SMARCB1 level and/or activity in a tumor sample obtained from the subject as compared to a reference level.

Abstract: This disclosure features compounds of Formula I (and their pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said compounds are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: In a method for determining a target processing state of a cooking product to be treated using a cooking appliance, a set of images of the cooking product in different processing states is provided to a user, with measurement signatures being stored for the images. When the user selects one of the images, the cooking appliance assumes a corresponding one of the measurement signatures associated with the selected image as a target measurement signature.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased ATM level and/or activity in a tumor sample obtained from the subject as compared to a reference level.

Abstract: Systems, methods, and computer-readable media are disclosed for visual labeling of training data items for training a machine learning model. Training data items may be generated for training the machine learning model. Visual labels, such as QR codes, may be created for the training data items. The creation of the training data item and the visual label may be automated. The visual labels and the training data items may be combined to obtain a labeled training data item. The labeled training data item may comprise a separator to distinguish the training data item from the visual label. The labeled training data item may be used for training and validation of the machine learning model. The machine learning model may analyze the training data item, attempt to identify the training data item, and compare the identification against the embedded label.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased ATR level and/or activity in a tumor sample obtained from the subject as compared to a reference level.

Abstract: Text-to-speech translation is used to generate a transcript for an audio file. Text segments are associated with time segments in the transcript. A trained machine learning model determines, based on the text in the transcript, one or more topics for the audio file. The transcript is modified to include the determined one or more topics. A user interface may be presented that allows a user to search for portions of an audio file that relate to a particular topic. In response to the selected or entered topic, the user interface presents segments having a matching topic. The user may use voice or other user interface commands to modify the annotation of the audio file. User commands may also be used to extract data from the transcript and copy the data to a clipboard or to another application.

Abstract: A bipartite graph is created that represents related metadata and datasets. The graph comprises disjoint and independent sets D (datasets) and M (metadata entries). For each dataset in the collection that has corresponding metadata, a relation is created in the graph between the node in D for the dataset and the node in M for the metadata. A vector embedding is generated for each dataset and metadata entry. New relations are added to the graph to relate datasets having similar embeddings. The graph is enriched by the new relations, enabling new kinds of search queries as well as recommendations and suggestions.

Abstract: Datasets are available from different dataset servers and often lack well-defined metadata. Thus, comparing datasets is difficult. Additionally, there might be different versions of the same dataset which makes the search even more difficult. Using systems and methods described herein, quality scores, dataset versioning, topic identification, and semantic relatedness metadata is stored about datasets stored on dataset servers. A user interface is provided to allow a user to search for datasets by specifying search criteria (e.g., a topic and a minimum quality score) and to be informed of responsive datasets. The user interface may further inform the user of the quality scores of the responsive datasets, the versions of the responsive datasets, or other metadata. From the search results, the user may select and download one or more of the responsive datasets.

Abstract: Example methods and systems are directed to automatic data card generation for datasets. A data card is a summary that describes quantitative aspects of a dataset, qualitative aspects of a dataset, or both. The data samples and documentation of a dataset are analyzed automatically to determine a number of samples, a primary data type, a license, or any suitable combination thereof. Data formats for data and documentation of the dataset may be automatically recognized. Language of text data may be automatically recognized. The most frequent language for the text data may be identified as the primary language of the dataset. A data card may be created for the dataset. The data card may indicate the number of samples, the data formats used in the data set, the language of text data in the dataset, or any suitable combination thereof.

Abstract: An input image is divided into segments. The segments may be reassembled to reform the input image. The order of the segments may be stored in an encrypted database for which approved applications have the decryption key but users do not. This allows the approved applications to determine the order and reform the input image without allowing users to do the same. To further increase the difficulty of reforming the input image, the segments may be transformed. Example transformations include rotation and mirroring. The encrypted database may store an indication of the transformation applied to each segment. The effort of reforming the input image without access to the database is increased substantially. The reformed input image may be stored in transient memory only, without being stored to long-term storage. Thus, the reformed image cannot be accessed from a file system by unauthorized users.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.